Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations

Medicine, Oncology, Treatment Planning +14

B cells are associated with survival and immunotherapy response in sarcoma

Florent Petitprez, Aurélien de Reyniès, Emily Z. Keung et al. · Nature · 2020 · 1.9K citations · Full text

Medicine, Immunology, Oncology +17

Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial

Hussein A. Tawbi, Melissa Burgess, Vanessa Bolejack et al. · The Lancet Oncology · 2017 · 1.4K citations · Full text

Medicine, Oncology, Pharmacology +13

Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆

Alessandro Gronchi, Aisha Miah, Angelo Paolo Dei Tos et al. · Annals of Oncology · 2021 · 989 citations · Full text

Medicine, Oncology, Surgery +14

Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials

Sandra P. D’Angelo, Michelle R. Mahoney, Brian Andrew Van Tine et al. · The Lancet Oncology · 2018 · 748 citations · Full text

Medicine, Oncology, Pharmacology +11